Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy

The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.

L-R: Chirfi Guindo, chief marketing officer, human health; Marjorie Green, head of late-stage oncology development; Gregory Lubiniecki, VP late oncology development; Eliav Barr, chief medical officer, Merck Research Laboratories; Dean Li, president, Merck Research Laboratories • Source: Alaric DeArment

Fresh off a raft of data presentations at the American Society of Clinical Oncology’s 2023 meeting, Merck & Co., Inc. laid out an oncology product development strategy in which immuno-oncology and antibody-drug conjugates (ADC) will play a leading role, along with small-molecule drugs.

Executives from the company assembled for a 5 June investor event in Chicago to lay out how the company plans...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ASCO

More from Conferences